고령 유방암 환자의 아베마시클립 및 내분비 요법.
이전 CDK 4/6 억제 도중 또는 이후에 진행된 호르몬 수용체 양성 전이성 유방암이 있는 70세 이상의 환자에서 내분비 요법과 병용하여 아베마시클립의 내약성을 평가하는 IIA상 시험
This phase IIa trial studies the side effects of abemaciclib monotherapy in treating patients age 70 years and older with hormone receptor positive, HER2 negative breast cancer that has spread to other places in the body.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
PRIMARY OBJECTIVE:
I. To estimate the incidence of grade 3 or higher toxicities attributed to abemaciclib monotherapy in adults aged 70 or older with hormone receptor positive metastatic breast cancer.
SECONDARY OBJECTIVES:
I. To describe the full toxicity profile including all grade 2 and higher adverse events, and patient-reported adverse events (AEs) using Patients Reported Outcomes (PRO)-Common Terminology Criteria for Adverse Events (CTCAE) measures.
II. To describe rates of dose reductions, dose holds, treatment discontinuations due to factors other than progression, and hospitalizations.
III. To estimate median (and 95% confidence interval [CI]) failure-free survival, progression-free survival and overall survival.
IV. To describe the results of Was It Worth It (WIWI) and Overall Treatment Utility (OTU) questionnaires.
V. To describe the rate of adherence to abemaciclib. VI. To determine average plasma steady-state abemaciclib Ctrough concentrations.
VII. To evaluate the association of adherence rate with abemaciclib plasma t-rough concentrations.
VIII. To describe associations between cancer-specific, comprehensive Geriatric Assessment (cGA) scores and the incidence of toxicities and their grade.
EXPLORATORY OBJECTIVE:
I. To determine the association between biomarkers of aging and grades 3 or higher toxicity.
OUTLINE:
Patients receive abemaciclib orally (PO) twice daily (BID) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 30 days, then every 6 months for 2 years.
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 2 단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Joanne Mortimer, MD
- 전화번호: 626-359-8111
- 이메일: jmortimer@coh.org
연구 장소
-
-
California
-
Duarte, California, 미국, 91010
- 모병
- City of Hope Medical Center
-
연락하다:
- Mina Sedrak
- 전화번호: 89200 626-256-4673
- 이메일: msedrak@coh.org
-
수석 연구원:
- Mina Sedrak
-
Irvine, California, 미국, 92618
- 모병
- City of Hope at Irvine Lennar
-
연락하다:
- Thanh Nga Doan
- 전화번호: 6262184673
- 이메일: tdoan@coh.org
-
Long Beach, California, 미국, 90813
- 모병
- City of Hope at Long Beach Elm
-
연락하다:
- Thanh Nga Doan
- 전화번호: 6262184673
- 이메일: tdoan@coh.org
-
South Pasadena, California, 미국, 91030
- 모병
- City of Hope South Pasadena
-
연락하다:
- Thanh Nga Doan
- 전화번호: 6262184673
- 이메일: mrosenzweig@coh.org
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02215
- 모병
- Dana Farber Cancer Institute
-
연락하다:
- Rachel Freedman, MD
- 전화번호: 617-632-3000
- 이메일: Rachel_Freedman@dfci.harvard.edu
-
-
New York
-
Buffalo, New York, 미국, 14203
- 모병
- Roswell Park Comprehensive Cancer Center
-
연락하다:
- Ellis Levine, MD
- 전화번호: 1-800-767-9355
- 이메일: Ellis.Levine@RosewellPark.org
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
Documented informed consent of the participant
-
Age >= 70 years
-
Life expectancy > 6 months
-
Ability to read and understand English or Spanish
-
Measurable or non-measurable disease
-
Histologically or cytologically confirmed diagnosis of:
- Estrogen-receptor positive and/or progesterone receptor positive breast cancer determined by immunohistochemistry (IHC) methods according to the local institution standard protocol
- HER2-negative breast cancer defined as negative if the IHC status is 0 or 1+, or if IHC is 2+ and in situ hybridization assay is negative per American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines
-
Radiographically confirmed metastatic breast cancer
-
Progressed on prior endocrine therapy or palbociclib or ribociclib or chemotherapy
-
Patients who received chemotherapy recovered from the acute side effects to prior cancer therapy (except alopecia or residual grade 2 peripheral neuropathy) to =< grade 1 or baseline. A washout period of at least 21 days is required between last chemotherapy dose and randomization (provided the patient did not receive radiotherapy)
-
Patients who received radiotherapy must have completed and fully recovered from the acute effects of radiotherapy. A washout period of at least 14 days is required between end of radiotherapy and randomization
-
Absence of central nervous system (CNS) involvement unless they meet ONE of the following criteria:
-
Untreated brain metastases (e.g., lesions < 1 cm) not needing immediate local therapy
-
Previously treated brain metastases not needing immediate local therapy
- At least 4 weeks from the last date of prior therapy completion (including radiation and/or surgery) to starting the study treatment
- Clinically stable CNS tumor at the time of screening and not receiving steroids and/or enzyme-inducing anti-epileptic medications for brain metastases
-
-
Absence of interstitial lung disease/pneumonitis
-
Absolute neutrophil count (ANC) >= 1.5 X 10^9/L
-
Platelets >= 100 x 10^9/L
-
Hemoglobin >= 8 g/dL
- (Patients may receive erythrocyte transfusions to achieve this hemoglobin level at the discretion of the investigator. Initial treatment must not begin earlier than the day after the erythrocyte transfusion)
-
In the absence of liver metastases, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 x upper limit of normal (ULN)
- If the patient has liver metastases, ALT and AST < 5 x ULN
-
In patients without Gilbert's syndrome, total bilirubin =< 1.5 x ULN; In patients with Gilbert's syndrome, total bilirubin =< 2.0 x ULN or direct bilirubin within normal limits (WLN)
-
Creatinine clearance of >= 30 mL/min per 24 hour urine test or the Cockcroft-Gault formula
Exclusion Criteria:
-
Major surgery within 14 days prior to receiving study drug or has not recovered from major side effect
-
Patient is currently receiving any of the prohibited medications detailed below and cannot be discontinued 7 days prior to starting study drug
- Other investigational therapy should be given to participants
- Anticancer agents other than the study medications administered as part of this study protocol should be given to participants. If such agents are required for a participant then the participant must first be withdrawn from the study
- Co-medication that may interfere with study results; e.g. immune-suppressive agents other than corticosteroids, such as systemic cyclosporine and tacrolimus are prohibited during the treatment phase of the study, unless discussed with principal investigator felt to be of low clinical risk to the participant
- Use of herbal medications may have unknown interactions with the metabolism of the study agents, and therefore are prohibited from use during the treatment phase of the trial
-
Known hypersensitivity to any of the excipients of abemaciclib
-
Active systemic bacterial infection (requiring intravenous [IV] antibiotics at time of initiating study treatment), fungal infection, or detectable viral infection (such as known human immunodeficiency virus positivity or with known active hepatitis B or C (for example, hepatitis B surface antigen positive). Screening is not required for enrollment
-
Impairment of gastrointestinal (GI) function or GI disease that in the investigator's opinion may significantly alter the absorption of the study drugs (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection)
-
History of any of the following conditions: syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin (including, but not limited to, ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest
-
Patient has any other concurrent severe or uncontrolled medical condition that would, in the investigator's judgment, cause unacceptable safety risks, contraindicate patient participation in the clinical study or compromise compliance with the protocol (e.g. chronic pancreatitis, chronic active hepatitis)
-
Inability to swallow oral medications
-
Serious or uncontrolled preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study (for example, interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, severe renal impairment [e.g. estimated creatinine clearance < 30 ml/min], history of major surgical resection involving the stomach or small bowel, or preexisting Crohn's disease or ulcerative colitis or a preexisting chronic condition resulting in baseline grade 2 or higher diarrhea)
-
History of non-compliance to medical regimen
-
Patients with a prior malignancy diagnosed within 2 years and with evidence of disease (except adequately treated, basal or squamous cell carcinoma, non-melanomatous skin cancer or curatively resected cervical cancer
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Treatment (abemaciclib)
Patients receive abemaciclib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. |
Ancillary studies Given PO
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Incidence of grade 3 or higher toxicities
기간: Up to 30 days post treatment
|
Adverse events will be characterized using the descriptions and grading scales found in the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v). 5.0. |
Up to 30 days post treatment
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
평균 혈장 정상 상태 아베마시클립 C-최저 농도
기간: 치료 후 최대 2년
|
치료 후 최대 2년
|
|
|
Incidence of toxicities
기간: Up to 30 days post treatment
|
Toxicities will be graded and named according to CTCAE v. 5.0. |
Up to 30 days post treatment
|
|
Incidence of toxicities
기간: Up to cycle 6
|
Toxicities will be captured by Patient Reported Outcome (PRO)-CTCAE. |
Up to cycle 6
|
|
Dose reductions
기간: Up to cycle 6
|
Will assess rates of dose reductions. |
Up to cycle 6
|
|
Dose holds
기간: Up to 30 days post treatment
|
Will assess rates of dose holds. |
Up to 30 days post treatment
|
|
Treatment discontinuations due to factors other than progression
기간: Up to 30 days post treatment
|
Will assess rates of treatment discontinuations. |
Up to 30 days post treatment
|
|
Hospitalizations
기간: Up to 2 years post treatment
|
Will assess rates of hospitalizations. |
Up to 2 years post treatment
|
|
Time to end of treatment
기간: Up to end of treatment
|
Will estimate median (and 95% confidence interval [CI]) failure-free survival using Kaplan-Meier estimates and through Cox regression to adjust for covariates. |
Up to end of treatment
|
|
Progression free survival
기간: Up to 2 years post treatment
|
Will estimate median (and 95% CI) progression-free survival using Kaplan-Meier estimates and through Cox regression to adjust for covariates. |
Up to 2 years post treatment
|
|
Overall survival
기간: Up to 2 years post treatment
|
Will estimate median (and 95% CI) overall survival using Kaplan-Meier estimates and through Cox regression to adjust for covariates. |
Up to 2 years post treatment
|
|
Was It Worth It (WIWI) response
기간: Up to end of treatment
|
Will be assessed using the WIWI questionnaire. |
Up to end of treatment
|
|
Overall treatment utility (OTU) response
기간: Up to end of treatment
|
Will be assessed using the OTU questionnaire. |
Up to end of treatment
|
|
Adherence to abemaciclib
기간: Up to end of treatment
|
Adherence defined as taking 90% of scheduled doses per cycle. Scheduled doses are assigned doses for the participant which may vary per participant depending on whether or not there a hold in treatment. Adherence will be calculated based on consolidation of pill diary with returned unused pills, and, for City of Hope (COH) Duarte patients, Medication Event Monitoring bottle caps. |
Up to end of treatment
|
|
Pharmacokinetic (PK) parameter of plasma trough concentration
기간: Up to 2 years post treatment
|
Will evaluate the association of adherence rate with abemaciclib plasma trough concentrations. |
Up to 2 years post treatment
|
|
Geriatric assessment scores
기간: Up to 2 years post treatment
|
Domains include: functional status, co-morbid medical conditions, cognitive function, nutritional status, social support and psychological state, and a review of medications. |
Up to 2 years post treatment
|
|
Incidence of toxicities attributable to agent
기간: Up to 2 years post treatment
|
Graded by CTCAE v 5.0. |
Up to 2 years post treatment
|
기타 결과 측정
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
디옥시리보핵산(DNA) 메틸화 수준을 통한 생물학적 연령
기간: 치료 후 최대 2년
|
치료 후 최대 2년
|
|
|
게놈 차원의 메틸롬 및 전사체 분석
기간: 치료 후 최대 2년
|
치료 후 최대 2년
|
|
|
Incidence of toxicities at least possibly attributable to agent
기간: Up to 2 years post treatment
|
Graded by CTCAE v 5.0. |
Up to 2 years post treatment
|
공동 작업자 및 조사자
협력자
협력자
수사관
수사관
- 수석 연구원: Joanne Mortimer, MD, City of Hope Medical Center
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- 19206
- P30CA033572 (미국 NIH 보조금/계약)
- 19206 (기타 식별자: City of Hope Medical Center)
- NCI-2019-08847 (레지스트리 식별자: CTRP (Clinical Trial Reporting Program))
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .